BeiGene GmbH's mission is to become a global leader in the discovery, development, and commercialization of innovative molecular-targeted immunologic drugs to treat cancer. BeiGene is a global, commercial-stage biotechnology company focused on the research, development, production and commercialization of innovative medicines. The company's products are mainly innovative drugs developed independently and innovated at the source. Through a collaborative approach of independent R&D and cooperative development, the company continues to expand its product pipeline. As of the signing date of this prospectus, the company's two drugs, BRUKINSA (BRUKINSA) and Baizean, have been conditionally approved for listing by the China Drug Administration, and BRUKINSA (BRUKINSA) has also received accelerated approval for listing by the US FDA.
No Data
No Data
No Data
No Data
No Data
No Data
No Data
No Data
No Data
No Data
No Data
No Data
No Data
No Data
No Data
No Data
No Data